ÂÜÀòÂÒÂ×

Davide Audisio has a diverse work experience in the field of chemistry. Davide started their career as a Master Degree Intern at the UMR CNRS 8612 Pharmacologie Cellulaire et Moléculaire des anticancéreux in 2006. Davide then pursued a PhD in Medicinal Chemistry at the Université Paris Sud, UMR-CNRS 8076, BioCIS, where they worked on the synthesis of novobiocin derivatives as potential Hsp90 inhibitors. After completing their PhD, Davide worked as a Postdoctoral Researcher at the Max Planck Institute for Coal Research, focusing on asymmetric catalysis and the development of enantio- and diastereoselective synthesis of substituted cyclobutenes. Davide later joined Eli Lilly and Company as a Contractor, Organic Chemist before transitioning to the CEA - Commissariat à l'énergie atomique et aux énergies alternatives. At CEA, Davide served as the Head of the Carbon14 Labeling Laboratory (LMC) and as a Senior Research Scientist. In their role at CEA, they were involved in research on carbon radiolabeling, catalysis, helicene and poly-aromatic chemistry, and chemistry of mesoionic heterocycles.

Davide Audisio studied at the Università degli Studi di Torino from 2000 to 2006, earning a Master of Science (MS) in "Pharmaceutical Chemistry and Technologies" with a focus on Pharmacy.